DailyIQ
|
Sector:HealthcareAll sectors
Last updated 6 minutes ago

GEHC·GE HealthCare Technologies Inc.

$.
+. (+.%)
After Hours
High
$65.25
Open
$64.93
Market Cap
29.43B
52W High
$89.77
Low
$64.14
P. Close
$64.70
P/E
15.41
52W Low
$58.75
Fwd P/E
12.06
DailyIQ Est.
$81.59
Technical Score (1D)
55
BUY
News Sentiment
50
MIXED
GE HealthCare announced a partnership with Mayo Clinic to develop adaptive cancer theranostics, combining imaging, biomarkers, and clinical data from the MI‑BET study. The collaboration leverages GEHC’s AI‑driven imaging portfolio and Mayo’s clinical expertise to refine diagnostic algorithms and accelerate the pipeline of targeted diagnostic and treatment agents. By integrating imaging and therapy platforms, the deal could bring new revenue streams and broaden GEHC’s oncology portfolio if the joint pipeline advances through clinical trials. This positions GEHC to capture a growing market for precision oncology solutions, potentially strengthening its competitive edge in the near term. Over the next 1–10 trading days, investors should watch for updates on trial milestones or regulatory filings that could validate the commercial upside. Pay particular attention to any press releases announcing phase‑I or phase‑II results, as these milestones could materially influence earnings expectations. Also monitor GEHC management commentary on integration timelines and resource allocation for the theranostics program. Finally, any regulatory approval or extension of the partnership would be a key catalyst for the stock’s near‑term trajectory.
Earnings Summary
GE HealthCare Technologies Inc. (GEHC) is a global medical technology leader focused on diagnostic imaging, patient monitoring, and pharmaceutical diagnostics, operating across advanced imaging systems, ultrasound, and radiopharmaceuticals. In the last two quarters, GEHC reported revenue of $5.698 billion in Q4 2025 and $5.131 billion in Q1 2026, a modest decline from the $5.143 billion and $5.007 billion of Q3 2025 and Q2 2025, respectively, while EPS fell from $1.44 to $0.99, missing the $1.04997 consensus; prior quarters saw consistent EPS beats, with Q4 2024, Q1 2025, Q2 2025, and Q3 2025 all exceeding estimates. Over the past year, revenue has accelerated from $4.777 billion in Q1 2025 to $5.698 billion in Q4 2025, reflecting a rebound after an early decline, though EPS growth has been uneven, with a peak in Q4 2025 followed by a dip in Q1 2026. The company’s revenue growth has been volatile, with a 12% rise in Q4 2025 versus Q3 2025 but a 10% drop in Q1 2026, while EPS growth peaked in Q4 2025 before declining, underscoring the need to monitor profitability metrics. Recent developments include a prostate cancer therapy study with Mayo Clinic and the MI‑1BET theranostics collaboration, both expanding GEHC’s oncology footprint, as well as AI‑enabled upgrade modules for legacy imaging suites that could generate incremental revenue through retrofits; these initiatives may influence investor sentiment and future earnings. Investors should watch for the Q2 2026 earnings release, regulatory filings related to the oncology studies, and the adoption pace of the AI upgrade program, as these factors will shape guidance and valuation in the coming quarter.

EPS

EstBeatMiss
$0.83$1.01$1.18$1.35$1.52Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.03 - -
Q1'26$1.05$0.99-5.7%
Q4'25$1.43$1.44+1.0%
Q3'25$1.05$1.07+2.2%
Q2'25$0.92$1.06+15.4%
Q1'25$0.91$1.01+10.6%

Revenue

EstBeatMiss
$4.6B$4.9B$5.3B$5.6B$5.9BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$5.4B - -
Q1'26$5.0B$5.1B+2.1%
Q4'25$5.7B$5.7B-0.4%
Q3'25 - $5.1B -
Q2'25 - $5.0B -
Q1'25 - $4.8B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

GEHC Stock Snapshot

GEHC is currently trading at $64.84, giving GE HealthCare Technologies Inc. a market cap of 29.43B and a P/E ratio of 15.4. Today's range spans $64.14–$65.25, with shares opening at $64.93 and moving up $0.14 (0.2%) from the prior close. DailyIQ's technical score sits at 55/100 (HOLD) with a news sentiment reading of 50/100.

Over the past year GEHC has traded between $58.75 and $89.77 - the current price is +10.4% off the 52-week low and -27.8% from the high. 30 analysts cover the stock with a Buy consensus and a mean 12-month target of $78.95 (range $65.00–$98.00), implying upside of +21.8%.

Neutral technical setups in large-cap Healthcare names are inherently unstable - they resolve. Right now, GEHC (55/100, HOLD, price $64.84, in the lower half of its 52-week range) is waiting for that resolution. Sentiment: neutral at 50/100. The current P/E ratio stands at 15.4. With 29.43B in market cap, the 52-week range of $58.75–$89.77 is where structural support and resistance live - and which one holds when the next catalyst hits will define the next trade.

The 52-week range of $58.75–$89.77 for GEHC provides the structural reference that options traders, systematic funds, and discretionary managers all anchor to — and at $64.84 (in the lower half of its 52-week range), the stock sits in a zone where the next 5–10% move will likely define which crowd was right. A HOLD signal at 55/100 and neutral news backdrop (50/100) don't break the tie yet, but they narrow the probability distribution toward the upside.